Zimmer Biomet — Oct 30, 2024 release

  Page 4 of 23   Financial Guidance The Company is updating its full-year 2024 financial guidance to reduce and narrow its previous projected ranges for revenue growth and adjusted 1 diluted EPS: Projected Year Ending December 31, 2024     Previous Guidance Updated Guidance 2024 Reported Revenue Change 4.0% - 5.0% 3.5% - 4.0% Foreign Currency Exchange Impact (1.0)% (0.75)% 2024 Constant Currency Revenue Change 5.0% - 6.0% 4.25% - 4.75% Adjusted Diluted EPS (1) $8.00 - $8.15 $7.95 - $8.05   (1) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.   Conference Call The Company will conduct its third quarter investor conference call today, October 30, 2024, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. W